Results 1 to 10 of about 126,257 (198)
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background It remains unclear whether beta‐blocker use at hospital admission is associated with better in‐hospital outcomes in patients with acute decompensated heart failure.
Yodo Tamaki +22 more
doaj +3 more sources
J Educ Teach Emerg MedThis simulation is intended to be used for emergency medicine (EM) residents (all levels) and 4th year medical students.Beta-blocker (BB) toxicity ranks seventh among the top 25 substances associated with fatalities, with a cardiovascular mortality rate of up to 1.4%.1,2 Patients with BB overdose may present with bradydysrhythmias, hypotension ...
Vempati A, Greene PJ.
europepmc +4 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017 BackgroundRelevant clinical studies have been small and have not convincingly demonstrated whether the perioperative initiation of beta‐blockers should be considered in patients with diabetes mellitus undergoing noncardiac surgery.
Ray‐Jade Chen +2 more
doaj +3 more sources
Molecules, 2022 Beta-blockers are antihypertensive drugs and can be abused by athletes in some sport competitions; it is therefore necessary to monitor beta-blocker levels in biological samples.
Aliya Nur Hasanah +2 more
doaj +3 more sources
Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia [PDF]
Annals of HematologyAllogeneic hematopoietic stem cell transplantation (HSCT) is curative for patients with acute myeloid leukemia (AML) through an immune-mediated graft-versus-leukemia effect, but relapse is common. Studies in solid tumors have shown that adrenergic stress
Johanna Werk +9 more
doaj +2 more sources
The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants [PDF]
Clinical and Translational SciencePrevious pharmacogenetic findings for beta‐blocker pharmacodynamic candidate genes (ADRB1, ADRB2, ADRA2C, GRK4, and GRK5) have been inconsistent. Therefore, the purpose of this study was to determine whether interactions of pharmacodynamic variants with ...
Jasmine A. Luzum +5 more
doaj +2 more sources
Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib [PDF]
MedicinaBackground and Objectives: Erlotinib, a tyrosine kinase inhibitor (TKI), is an established therapy for patients with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations.
Oğuzhan Yıldız +9 more
doaj +2 more sources
Persistent Beta‐Blocker Therapy Reduces Long‐Term Mortality in Patients With Acute Ischemic Stroke With Elevated Heart Rates [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground Elevated heart rate in patients with acute ischemic stroke is associated with increased risk of mortality. Beta‐blocker therapy is well known to reduce heart rate.
Keon‐Joo Lee +35 more
doaj +2 more sources
Medicina, 2023 Background and Objectives: Osteoporosis results in increasing morbidity and mortality in hemodialysis patients. The medication for treatment has been limited.
Suthiya Anumas +4 more
doaj +1 more source
Beta-blockers for hypertension [PDF]
Cochrane Database of Systematic Reviews, 2017 Beta-blockers refer to a mixed group of drugs with diverse pharmacodynamic and pharmacokinetic properties. They have shown long-term beneficial effects on mortality and cardiovascular disease (CVD) when used in people with heart failure or acute myocardial infarction. Beta-blockers were thought to have similar beneficial effects when used as first-line
Wiysonge, Charles S. +4 more
openaire +3 more sources